| Name | Title | Contact Details |
|---|---|---|
Scott Sarris |
Chief Information Security Officer | Profile |
Proactis is a Calgary, AB-based company in the Software and Internet sector.
Clyde Golden is a creative agency in Seattle. We use research, strategy, and content to activate brands via Customer Journey programs.
ZeroEyes delivers a proactive, human-verified A.I. gun detection software solution that integrates into existing security cameras and mitigates mass shootings and gun-related violence by reducing response times, providing actionable intelligence with images and delivering clarity among chaos – ultimately saving lives. ZeroEyes` patented solution has been recognized by the U.S. Department of Homeland Security (DHS) as a promising anti-terrorism technology and is the first video analytics technology to receive SAFETY Act DT&E Designation. Founded by Navy SEALs and Special Operations military veterans, ZeroEyes delivers accurate and real-time actionable intelligence about the brandishing of a gun near or in an occupied area or building, to local staff and law enforcement with an image of the shooter(s) and location of the threat, within 3 to 5 seconds from the moment the gun is detected. The ZeroEyes team also provides tech consulting, installation assistance and practice drills for active shooter events to enhance safety at schools, corporate and government facilities. Headquartered in the Greater Philadelphia area, the company`s affordable and effective gun detection solution has been adopted by the US Department of Defense, leading public K-12 school districts, colleges / universities, commercial property groups, manufacturing plants, Fortune 500 corporate campuses, shopping malls, big-box retail stores and more.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Cavium (NASDAQ: CAVM) is a provider of highly integrated semiconductor processors that enable intelligent networking, communications, storage, video and security applications. Cavium offers a broad portfolio of integrated, software compatible processo...